Tue, Sep 2, 2014, 5:37 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

dinepat203 324 posts  |  Last Activity: 3 hours ago Member since: Sep 29, 2011
  • Reply to

    Reuters article posted part1

    by homework.investwell Jun 19, 2014 7:59 PM
    dinepat203 dinepat203 Jun 19, 2014 8:05 PM Flag

    1. Buzdar, an oncologist by training, spoke by phone about Northwest Bio on Wednesday
    ( Wednesday 18th June 2014 - Buzdar is available only at his clinic 1515 Holcombe Blvd Houston, TX 77030 (713) 792-6161. during 8:00 AM - 12:00 PM and 1:00 PM - 5:00 PM - No phone call conversation with any STOCK BLOGGER - Secretary confirmed)

    2. But Buzdar said investigators at MD Anderson and the two other hospitals conducting the DCVAX-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.
    ( How and Why Buzdar comment about other hospitals conducting trials?)

    3. First AF writes that according to Dr. Aman U. Buzdar - NWBO made statement first that NWBO disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. ( Note here the information is from Individual Patients) then Dr. Aman U. Buzdar made - The statements being made by Northwest Bio about DCVax-Direct are derived from patient case report forms, which the hospitals are obliged to send to the company because it sponsored the study.

    How come Dr.Aman U. Buzdar make 2 statements ? -
    1 Results are directly from Patients and
    2. From Patients case report which MD Anderson obliged to send to company .

  • Reply to

    AF = 3 Lies identified

    by dinepat203 Jun 19, 2014 7:42 PM
    dinepat203 dinepat203 Jun 19, 2014 8:01 PM Flag

    Can SEC investigate this as Mkt manipulations ?

  • dinepat203 by dinepat203 Jun 19, 2014 7:42 PM Flag

    1. Buzdar, an oncologist by training, spoke by phone about Northwest Bio on Wednesday
    ( Wednesday 18th June 2014 - Buzdar is available only at his clinic 1515 Holcombe Blvd Houston, TX 77030 (713) 792-6161. during 8:00 AM - 12:00 PM and 1:00 PM - 5:00 PM - No phone call conversation with any STOCK BLOGGER - Secretary confirmed)

    2. But Buzdar said investigators at MD Anderson and the two other hospitals conducting the DCVAX-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.

    ( How and Why Buzdar comment about other hospitals conducting trials?)

    3. First AF writes that according to Dr. Aman U. Buzdar - NWBO made statement first that NWBO disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. ( Note here the information is from Individual Patients)

    then Dr. Aman U. Buzdar made - The statements being made by Northwest Bio about DCVax-Direct are derived from patient case report forms, which the hospitals are obliged to send to the company because it sponsored the study.

    How come Dr.Aman U. Buzdar make 2 statements ? -
    1 Results are directly from Patients and
    2. From Patients case report which MD Anderson obliged to send to company .

  • dinepat203 dinepat203 Jun 19, 2014 3:51 PM Flag

    That is some amazing results. I wonder since it is a small company producing it they would be more or less likely to give the drug to one of us on a compassionate basis.

    DX 10-05 stage IV
    liver resection 12-05
    Folfox + Avastin 1-05 to 7-06
    Liver resection 8-07
    Folfiri + Avastin 9-07 to 3-08
    DVT resulting in angioplasty 1-08
    Liver resection 12-11
    Clean scan finished chemo 7-9-12
    Clean scan 7-10-13

  • Personally my interest in this technology is because of the concept of a dendritic cell vaccine. Ralph Steinman won a Nobel Prize in 2011 for his discovery of the role of dendritic cells in adaptive immunity. If one's own immune system can recognize and memorize the characteristics of cancer cells, then cancer would have a hard time to to take hold in one's body (Dendritic cell functions to teach the immune system to recognize other cells).

    Past attempts of dendtritic cells cancer treatment involved the use of immature dendritic cells. What's different about DCVax-Direct is the dendtritic cells used here is partially matured then injected back into the tumor. Supposedly this will allow the DC cells to better pickup tumor antigens.

    Since this technology is from a tiny development stage biotech company based in Maryland, it lacks the marketing prowess of a Merck or a Roche, so you won't hear much about it from the mainstream media. But in concept, the vaccine approach to cancer treatment is just as if not more promising than all the immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4) that are all the buzz right now.

  • dinepat203 dinepat203 Jun 19, 2014 3:45 PM Flag

    company released additional case studies. You can find some some of the more interesting tidbits below:

    in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have received 4 of the 6 planned injections are showing tumor cell death, tumor shrinkage, substantial immune cell accumulation in their tumors and/or stabilization (i.e., stopping the progression) of their advanced cancer. In addition, in 3 of these 9 patients, biopsies now show no live tumor cells in the injected tumor.

    biopsies taken in 3 of these 9 patients now show no live tumor cells in the tumor that was injected. These 3 cases include diverse, advanced and particularly aggressive cancers: 1 metastatic pancreatic cancer case, 1 metastatic colon cancer case and 1 metastatic sarcoma case. ...Each of these 3 patients was treated with the lowest dose level (2 million cells per treatment).

  • Has anyone looked into this clinical trial DCVax-Direct at MD Anderson in Houston and Orlando for all inoperable solid tumor cancers including colon cancer? Dendtric cell using all of the tumors biomarkers and antigens has displayed very positive results in earlier trials. Anyone that has enrolled your feedback is much appreciated.
    My husband and I inquired about this trial while we were down in Florida about two weeks ago. This has only been done on a handful of humans at this time. It is a promising one though! My husband is excluded due to now needing anticoagulant therapy. The research coordinator down there said that she has seen more interest in this particular trial than any she has been associated with. Anyway, no one on this board, that I know of, has been accepted to this trial.

    DH 51 yo
    dx 5/16/11 stg 4 RC
    mets both lobes liver & lung
    6/11 chemo/rad
    FOLFOX 9-12/11
    12/11 TME/liver resect/rfa (15 tumors)
    2-3/12 4 more rounds Folfox - 2 w/Avastin
    5/12 innumerable mets liver
    Folfox/Avas FAIL
    9/12 FOLFIRI/Erb FAIL
    HAI pump 12/12

  • dinepat203 dinepat203 Jun 19, 2014 3:35 PM Flag

    With NWBO reply and DCVax interim this would be $70 or above

  • dinepat203 dinepat203 Jun 19, 2014 3:33 PM Flag

    INTERIM RESULTS IS COMING ....

  • with 41 years of practice in the field Patients rate Him 1 out of 4 stars.
    But he must contact Dr. Vivek.
    MD ANDERSON - PR as follows..............
    Early-stage trials of a sister drug, DCVax-Direct, are targeting a wide range of other solid tumors so advanced or inaccessible that they are deemed inoperable.

    The trials of DCVax-Direct involve 60 U.S. patients. The Phase 1 stage will focus primarily on safety, although hints of efficacy could emerge. The primary goal of the Phase II part of the study is to shrink or eliminate tumors.

    Dr. Vivek Subbiah, an oncologist at M.D. Anderson Cancer Center in Houston who is leading the DCVax-Direct trials, said he may present initial data at the annual meeting of the American Society of Clinical Oncology that begins May 30.

    Subbiah and his colleagues test scores of experimental cancer drugs, many having new mechanisms of action.

    "This is not a 'me-too' trial," Subbiah said. "It is one of the interesting technologies. Twenty years ago it was chemo, 10 years ago it was targeted therapies, and for this decade it will be drugs that boost the immune system."

  • dinepat203 dinepat203 Jun 19, 2014 3:15 PM Flag

    This DOC is just limited to Breast and has no idea of how brain cancer be treated...Cheers LOL AF - Your opinion leader has no background what so ever.

  • dinepat203 dinepat203 Jun 19, 2014 3:12 PM Flag

    Boris Peaker, an analyst with Oppenheimer & Co, noted the ongoing Phase III trial has the involvement of many more doctors and a more genetically diverse population of patients.

    "If the drug holds up in Phase III, it will be a very big win for the company because there aren't many good options now for patients, and DCVax is certainly better tolerated than any chemotherapy," Peaker said. "And if it works in brain cancer, it should work in other solid tumors."

  • dinepat203 dinepat203 Jun 19, 2014 3:10 PM Flag

    Why Adam called this Aman U Buzdar, BS, when DCVax Direct clinical trials are under Dr. Vivek Subbiah, an oncologist at M.D. Anderson Cancer Center in Houston who is leading the DCVax-Direct trials

  • dinepat203 dinepat203 Jun 19, 2014 2:51 PM Flag

    Adam might give him 5 Star Rating -LOL-- JOKE

  • 1 star out of 4

    Internists, Oncology Specialist (cancer)
    43 years of experience
    Video profile
    Accepting new patients
    Medical Center
    M D Anderson Cancer Ctr
    1515 Holcombe Blvd
    Houston, TX 77030
    713-792-6161
    Locations and availability (1)

    May 9th, 2012
    Unfortunately, hoping I would meet an overall caring doctor, he was nothing at all like what I hoped. He was condescending and lacked a show of respect overall. Coincidently, comparing notes with a friend, the same thing had happened to her. I'm looking elsewhere.

    Currently 1 of 4 stars
    REFUSED TO GIVE HIS MEDICAL OPINION | show details
    By confused from CA on Apr 11th, 2010

    I have a very small cancer and am HER2+ and had received 3 conflicting opinions. Dr. Buzdar was supposed to be the tiebreaker. Despite me flying all the way from CA to TX and wasting all my time & money, Dr. Buzdar refused to give me a medical opinion on what I should do with regards to chemo or no chemo. He just kept saying "either one is reasonable" and would not take a stand unlike every other dr I had seen. Also, when asked which chemo cocktail he'd put me on if I did choose chemo, he said "any one is reasonable". so he wouldn't commit to that either. i'm writing a letter to the chairman of oncology at md anderson to complain. DO NOT WASTE YOUR TIME OR MONEY WITH THIS DOCTOR. HE WILL NOT MAKE A MEDICAL DECISION!

  • And understood that Interim results are good to get FDA -AA approval for Phase-3 DCVax-L anytime soon.

    DCVax-L Vaccine Launch to Boost Glioblastoma Multiforme Market Value to $623 Million by 2020, According to a New Study on ASDReports
    Thursday 19 June 2014, Amsterdam

  • dinepat203 dinepat203 Jun 19, 2014 2:30 PM Flag

    This is a very old game in Pharma companies when MMS wants cheap from innocent retails.

  • Imagine a Blogger like AF, supported by Law firms putting ointment on wound and get more deep further and grab that all before Phase-3 results are out.

  • Linda will come back to answer all BS from AF which he does as usual.

  • dinepat203 dinepat203 Jun 19, 2014 1:02 PM Flag

    The new report: 'Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”.Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment.

    During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. The market entry of Northwest Biotherapeutics’ DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline.

AEGR
30.62+0.07(+0.23%)Sep 2 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.